Trials / Terminated
TerminatedNCT05100316
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
A Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive Cell Therapies in Participants With Solid Tumors and Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers. No treatment intervention will occur as part of this screening study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Screening Platform | Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study. |
Timeline
- Start date
- 2021-12-16
- Primary completion
- 2022-10-04
- Completion
- 2022-10-04
- First posted
- 2021-10-29
- Last updated
- 2024-02-05
- Results posted
- 2024-02-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05100316. Inclusion in this directory is not an endorsement.